D.E. Shaw & Co’s Pyxis Oncology PYXS Stock Holding History

D.E. Shaw & Co’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,367	Closed	-$114K	–	5856
2021 Q4	$114K	Buy	+10,367	New	+$119K	﹤0.01%	5037

Other funds holding PYXS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co's PYXS Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Pyxis Oncology (PYXS) in Q1 2022, closing a stake of 10,367 shares — an estimated $114K sold.

D.E. Shaw & Co first reported a position in PYXS in Q4 2021 and held it in 1 quarter. The position peaked at $114K in Q4 2021. 45 funds tracked by Wall St. Rank hold PYXS as of Q1 2022.

D.E. Shaw & Co reported no remaining Pyxis Oncology position as of Q1 2022 after selling out during the quarter.
D.E. Shaw & Co sold 10,367 Pyxis Oncology shares in Q1 2022, an estimated $114K.
D.E. Shaw & Co first reported a position in Pyxis Oncology in Q4 2021 and held it in 1 quarter.
D.E. Shaw & Co's Pyxis Oncology position peaked at $114K in Q4 2021.
45 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.